Advertisement

Topics

Agenus to leverage Selexis' modular SUREtechnology platform for rapid, stable, and cost─effective production of therapeutic proteins

11:00 EST 11 Jan 2019 | PharmaBiz

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, has signed additional commercial license agreements (CLAs) with Agenus Inc, an immuno─

Original Article: Agenus to leverage Selexis' modular SUREtechnology platform for rapid, stable, and cost─effective production of therapeutic proteins

NEXT ARTICLE

More From BioPortfolio on "Agenus to leverage Selexis' modular SUREtechnology platform for rapid, stable, and cost─effective production of therapeutic proteins"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...